<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "11: necessary regulatory approvals", fill: "#f3c"},
{source: "11: necessary regulatory approvals", target: "11: TriActiv ProGuard System ", fill: "#f3c"},
{source: "11: TriActiv ProGuard System ", target: "11: future generations", fill: "#f3c"},
{source: "11: future generations", target: "11: endovascular", fill: "#f3c"},
{source: "11: endovascular", target: "11: product platform", fill: "#f3c"},
{source: "11: product platform", target: "11: United States", fill: "#f3c"},
{source: "11: necessary regulatory approvals", target: "24: income from", fill: "#e0b0ff"},
{source: "24: income from", target: "24: biomaterials", fill: "#e0b0ff"},
{source: "24: income from", target: "25: associated with", fill: "#cfb53b"},
{source: "25: associated with", target: "25: AngioSeal ", fill: "#cfb53b"},
{source: "25: AngioSeal ", target: "25: approximately", fill: "#cfb53b"},
{source: "25: approximately", target: "25: biomaterials", fill: "#cfb53b"},
{source: "25: biomaterials", target: "25: distributor", fill: "#cfb53b"},
{source: "25: distributor", target: "25: total revenue", fill: "#cfb53b"},
{source: "25: total revenue", target: "25: to Orthovita ", fill: "#cfb53b"},
{source: "25: associated with", target: "30: revenues will continue", fill: "#009000"},
{source: "30: revenues will continue", target: "30: AngioSeal ", fill: "#009000"},
{source: "30: AngioSeal ", target: "30: manufactured marketed", fill: "#009000"},
{source: "30: manufactured marketed", target: "30: distributed by", fill: "#009000"},
{source: "30: revenues will continue", target: "36: Jude Medical ", fill: "#900"},
{source: "36: Jude Medical ", target: "36: in the AngioSeal ", fill: "#900"},
{source: "36: in the AngioSeal ", target: "36: of the AngioSeal ", fill: "#900"},
{source: "36: of the AngioSeal ", target: "36: product line", fill: "#900"},
{source: "36: Jude Medical ", target: "60: highly competitive", fill: "#ff3800"},
{source: "60: highly competitive", target: "60: competitive", fill: "#ff3800"},
{source: "60: competitive", target: "60: competitors may", fill: "#ff3800"},
{source: "60: competitors may", target: "60: emerging technologies", fill: "#ff3800"},
{source: "60: emerging technologies", target: "60: customer requirements", fill: "#ff3800"},
{source: "60: highly competitive", target: "63: biomaterials", fill: "#c9dc87"},
{source: "63: biomaterials", target: "63: medical devices compete directly", fill: "#c9dc87"},
{source: "63: medical devices compete directly", target: "63: indirectly", fill: "#c9dc87"},
{source: "63: indirectly", target: "63: customers with", fill: "#c9dc87"},
{source: "63: customers with", target: "63: technologies", fill: "#c9dc87"},
{source: "63: technologies", target: "63: procedures which", fill: "#c9dc87"},
{source: "63: procedures which", target: "63: competitors", fill: "#c9dc87"},
{source: "63: biomaterials", target: "START_HERE", fill: "#c9dc87"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Future_generations">Future generations</a></td>
      <td>Future generations are cohorts of hypothetical people not yet born. Future generations are contrasted with current and past generations, and evoked in order to encourage thinking about intergenerational equity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Future_Generations">Future Generations</a></td>
      <td>Future generations are cohorts of hypothetical people not yet born. Future generations are contrasted with current and past generations, and evoked in order to encourage thinking about intergenerational equity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Future_Generations_University">Future Generations University</a></td>
      <td>Future Generations University (formerly Future Generations Graduate School) is a global graduate school that offers a Master of Arts in Applied Community Development. Future Generations grew out of Future Generations, a non-governmental organization that began in the early 1990s in response to a UNICEF sponsored review of community-based initiatives worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kuwait_Investment_Authority">Kuwait Investment Authority</a></td>
      <td>The Kuwait Investment Authority (KIA) is Kuwait's largest sovereign wealth fund, managing body, specializing in local and foreign investment. \nFounded in 1953, it is the world's oldest sovereign wealth fund.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Ministry_for_the_Future">The Ministry for the Future</a></td>
      <td>The Ministry for the Future is a climate fiction ("cli-fi") novel by American science fiction writer Kim Stanley Robinson published in 2020. Set in the near future, the novel follows a subsidiary body, established under the Paris Agreement, whose mission is to advocate for the world's future generations of citizens as if their rights are as valid as the present generation's.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Future_Generations_(band)">Future Generations (band)</a></td>
      <td>Future Generations is an electro indie-pop band based in Brooklyn, NY.\n\n\n== Biography ==\nFuture Generations was formed by Eddie Gore, Eric Grossman, and Mike Sansevere, who met the first week of their freshman year at Fordham University in Bronx, NY in 2011, when they ran into each other by chance in their dorm building's shared practice room. Gore met Devon Sheridan in line to buy tickets for a school dance their junior year and asked him to play bass in the band.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_heritage_of_humanity">Common heritage of humanity</a></td>
      <td>Common heritage of mankind (also termed the common heritage of humanity, common heritage of humankind or common heritage principle) is a principle of international law that holds that defined territorial areas and elements of humanity's common heritage (cultural and natural) should be held in trust for future generations and be protected from exploitation by individual nation states or corporations.\n\n\n== Origins ==\nIn tracing the origins of the common heritage principle, it is important to distinguish its history as a term from its conceptual history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strauss–Howe_generational_theory">Strauss–Howe generational theory</a></td>
      <td>The Strauss–Howe generational theory, devised by William Strauss and Neil Howe, describes a theorized recurring generation cycle in American history and global history. According to the theory, historical events are associated with recurring generational personas (archetypes).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biomaterial">Biomaterial</a></td>
      <td>A biomaterial is a substance that has been engineered to interact with biological systems for a medical purpose, either a therapeutic (treat, augment, repair, or replace a tissue function of the body) or a diagnostic one. As a science, biomaterials is about fifty years old.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biomaterials_(journal)">Biomaterials (journal)</a></td>
      <td>Biomaterials is a peer-reviewed scientific journal covering research on and applications of biomaterials. It is published by Elsevier and the editor-in-chief is Kam W. Leong (Columbia University).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Artificial_Cells,_Nanomedicine,_and_Biotechnology">Artificial Cells, Nanomedicine, and Biotechnology</a></td>
      <td>Artificial Cells, Nanomedicine, and Biotechnology is a peer-reviewed scientific journal that publishes articles on the development of artificial cells, tissue engineering, artificial organs, blood substitutes, cell therapy, gene and drug delivery systems, bioencapsulation nanosensors, nanodevices, and other areas of biotechnology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biomaterial_surface_modifications">Biomaterial surface modifications</a></td>
      <td>Biomaterials exhibit various degrees of compatibility with the harsh environment within a living organism. They need to be nonreactive chemically and physically with the body, as well as integrate when deposited into tissue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biomaterials_Science">Biomaterials Science</a></td>
      <td>Biomaterials Science is a peer-reviewed scientific journal that explores the underlying science behind the function, interactions and design of biomaterials. It is published by the Royal Society of Chemistry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Foreign_body_reaction">Foreign body reaction</a></td>
      <td>A foreign body reaction (FBR) is a typical tissue response to a foreign body within biological tissue. It usually includes the formation of a foreign body granuloma.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fellow_of_Biomaterials_Science_and_Engineering">Fellow of Biomaterials Science and Engineering</a></td>
      <td>In April 1992, the constituent biomaterials societies of the World Biomaterials Congress, now the International Union of Societies for Biomaterials Science and Engineering (IUSBSE) experienced the need to recognize all their members who had a status of excellent professional standing and high achievements in the field of biomaterials science and engineering.\nThis was the beginning of the establishment of the honorary status of "Fellow, Biomaterials Science and Engineering" (FBSE).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/European_Society_for_Biomaterials">European Society for Biomaterials</a></td>
      <td>The European Society for Biomaterials (ESB) is a non-profit organisation that encourages research and spread of information regarding research and uses of biomaterials. Founded in March 1976, became a member of the International Union of Societies for Biomaterials Sciences and Engineering (IUS-BSE) at its conception, in 1979.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mechanical_properties_of_biomaterials">Mechanical properties of biomaterials</a></td>
      <td>Materials that are used for biomedical or clinical applications are known as biomaterials. The following article deals with fifth generation biomaterials that are used for bone structure replacement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vascular_closure_device">Vascular closure device</a></td>
      <td>Vascular closure devices (VCDs) are medical devices used to achieve hemostasis of the small hole in the artery after a cardiovascular procedure of endovascular surgery requiring a catheterization.\nCardiovascular procedures requiring catheterization include diagnostic procedures that help diagnose diseased blood vessels and interventional procedures such as angioplasty, the placement of a stent and coronary thrombectomy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/St._Jude_Medical">St. Jude Medical</a></td>
      <td>St. Jude Medical, Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Abbott_Laboratories">Abbott Laboratories</a></td>
      <td>Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Joanna_I_of_Naples">Joanna I of Naples</a></td>
      <td>Joanna I, also known as Johanna I (Italian: Giovanna I; December 1325 – 27 July 1382), was Queen of Naples, and Countess of Provence and Forcalquier from 1343 to 1382; she was also Princess of Achaea from 1373 to 1381.\nJoanna was the eldest daughter of Charles, Duke of Calabria and Marie of Valois to survive infancy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anna-Maria_Belli">Anna-Maria Belli</a></td>
      <td>Anna-Maria Belli, MD, FCIRSE is a British interventional radiologist known for her work in vascular interventional radiology and for holding leadership positions in interventional radiology societies in Britain and Europe.\n\n\n== Training and career ==\nBelli received her medical degree from the Middlesex Hospital Medical School (London, England) in 1980.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arecaceae">Arecaceae</a></td>
      <td>The Arecaceae is a family of perennial flowering plants in the monocot order Arecales. Their growth form can be climbers, shrubs, tree-like and stemless plants, all commonly known as palms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nymphaeaceae">Nymphaeaceae</a></td>
      <td>Nymphaeaceae () is a family of flowering plants, commonly called water lilies. They live as rhizomatous aquatic herbs in temperate and tropical climates around the world.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Muddy_Waters_Research">Muddy Waters Research</a></td>
      <td>Muddy Waters Research LLC is an American privately held due diligence based investment firm that conducts investigative research on public companies while also taking investment positions that reflect their research. The firm has exposed accounting problems and fraud at several companies, primarily in China but also in other countries in Asia, Europe and North America.The firm is best known for spotting fraud at Sino-Forest Corp, a Canadian-listed Chinese company whose stock fell 74 percent before it eventually filed for bankruptcy protection in March 2012.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Artificial_cardiac_pacemaker">Artificial cardiac pacemaker</a></td>
      <td>A cardiac pacemaker (or artificial pacemaker, so as not to be confused with the natural pacemaker of the heart) is a medical device that generates electrical impulses delivered by electrodes to cause the heart muscle chambers (the upper, or atria and/or the lower, or ventricles) to contract and therefore pump blood. By doing so, this device replaces and/or regulates the function of the electrical conduction system of the heart.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>KENSEY NASH CORP      ITEM 1A RISK FACTORS        You <font color="blue">should carefully</font> consider the risks, uncertainties and other factors     described below, in addition to the other information set forth in this     report, because they <font color="blue">could materially</font> and <font color="blue">adversely affect</font> our business,     operating results, financial condition, cash flows and <font color="blue">prospects as well as</font>     <font color="blue">adversely affect</font> the value of an <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Business        The  TriActiv FX System, the QuickCat catheter and the <font color="blue">ThromCat System     </font><font color="blue"><font color="blue">endovascular</font> products</font> were <font color="blue">recently introduced</font> or <font color="blue">gained <font color="blue">regulatory</font> approval</font>     in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If any or all of these <font color="blue">three products fail</font> to gain or     <font color="blue">lose market <font color="blue">acceptance</font></font>, our business will suffer</td>
    </tr>
    <tr>
      <td>We expect that sales of the TriActiv FX System, the QuickCat catheter and     the ThromCat system in the <font color="blue">United States</font> <font color="blue">will account</font> for a <font color="blue">significant</font>     portion of our revenue in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Because of their recent     commercial <font color="blue">introduction</font> and/or <font color="blue">regulatory</font> approval, these three products     have limited product and brand <font color="blue">recognition</font></td>
    </tr>
    <tr>
      <td>We do not know if these products     will  be <font color="blue">successful over</font> the long term</td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of the three     <font color="blue">products may</font> be hindered if physicians are not <font color="blue">presented with compelling</font>     data from long-term studies of the safety and efficacy of the products     compared to <font color="blue"><font color="blue">alternative</font> procedures</font></td>
    </tr>
    <tr>
      <td>We have no current plans to <font color="blue">conduct such</font>     <font color="blue">comparative studies</font></td>
    </tr>
    <tr>
      <td>In addition, demand for the <font color="blue">products may</font> not increase     <font color="blue">as quickly as</font> we expect</td>
    </tr>
    <tr>
      <td>Failure of the products to <font color="blue">significant</font>ly penetrate     current or <font color="blue">new markets would negatively impact</font> our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals for the     <font color="blue">TriActiv ProGuard System </font>or any <font color="blue">future generations</font> of the <font color="blue">endovascular</font>     <font color="blue">product platform</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The FDA has not cleared the <font color="blue">TriActiv ProGuard System </font>in carotid stenting     procedures for marketing nor have we completed the required clinical trials     and/or <font color="blue">regulatory</font> <font color="blue">submissions</font></td>
    </tr>
    <tr>
      <td>Prior to granting approval for commercial     sale or for the <font color="blue">commencement</font> of <font color="blue">clinical trials on</font> the ProGuard and other     <font color="blue">future generations</font> of the device, the FDA may require <font color="blue">clarification</font> of     information provided in our <font color="blue">regulatory</font> <font color="blue">submissions</font>, more information or more     <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>If granted, FDA <font color="blue">approval may impose limitations on</font> the     uses for which our <font color="blue">products may</font> be marketed or how our <font color="blue">products may</font> be     marketed</td>
    </tr>
    <tr>
      <td>Should we experience delays or be unable to receive <font color="blue">clearance from</font>     the FDA, our <font color="blue">growth prospects will</font> be diminished</td>
    </tr>
    <tr>
      <td>We may not be <font color="blue">successful commercializing current</font> or <font color="blue">future generations</font> of     our <font color="blue">endovascular</font> <font color="blue">product platform</font> through a <font color="blue">direct <font color="blue">sales force</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will <font color="blue">commercialize</font></font> the TriActiv FX System, which has <font color="blue">only recently been</font>     approved for sale in the <font color="blue">United States</font>, as well as <font color="blue">future generations</font> our     <font color="blue">endovascular</font> <font color="blue">product line</font> through a <font color="blue">direct <font color="blue">sales force</font></font></td>
    </tr>
    <tr>
      <td>We may not be able     to <font color="blue"><font color="blue">successfully</font> recruit</font>, develop and train our own <font color="blue">sales force</font> to sell and     market the TriActiv FX System, the QuickCat catheter, the ThromCat™ Device,     the ProGuard™ Device or other <font color="blue">future generations</font> of the                                           20     ______________________________________________________________________    [22]Table of <font color="blue">Contents       </font><font color="blue">endovascular</font> <font color="blue">product platform</font></td>
    </tr>
    <tr>
      <td>We began the <font color="blue">development</font> of a <font color="blue">direct sales</font>     and <font color="blue">marketing force</font> in fiscal 2005 and <font color="blue">must continue</font> to develop and expand     this  force</td>
    </tr>
    <tr>
      <td>We had no prior experience hiring or training a sales and     <font color="blue">marketing force</font> and may not be able to expand and maintain such a team with     adequate  technical  expertise  and  which  is  capable  of supporting     <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font> current</font> or     <font color="blue">future generations</font> of our <font color="blue">endovascular</font> devices, our <font color="blue">growth prospects will</font> be     diminished</td>
    </tr>
    <tr>
      <td>We derive a substantial majority of our <font color="blue">revenues from only three customers</font></td>
    </tr>
    <tr>
      <td>A substantial majority of our <font color="blue"><font color="blue">total revenue</font>s</font> are <font color="blue">derived from only three</font>     customers</td>
    </tr>
    <tr>
      <td>Royalty <font color="blue">income from</font>, and sales of <font color="blue">biomaterials</font> to, St</td>
    </tr>
    <tr>
      <td>Jude     Medical <font color="blue">associated with</font> the Angio-Seal represented <font color="blue">approximately</font> 57prca of our     total  revenue for fiscal 2006 while sales of <font color="blue">biomaterials</font> products to     Arthrex, a <font color="blue">distributor</font> of orthopaedic products, represented <font color="blue">approximately</font>     22prca of <font color="blue"><font color="blue">total revenue</font>s</font> and royalty <font color="blue">income from</font>, and sales of <font color="blue">biomaterials</font>     products <font color="blue">to Orthovita </font>represented <font color="blue">approximately</font> 10prca of <font color="blue">total revenue</font> for     fiscal 2006</td>
    </tr>
    <tr>
      <td>It is not possible for us to predict the future level of demand     for our products that will be <font color="blue">generated by</font> these customers or the future     demand for the Angio-Seal <font color="blue">from customers</font> of St</td>
    </tr>
    <tr>
      <td>Our customer     <font color="blue">concentration <font color="blue">exposes us</font></font> to the risk of changes in the business condition of     any of our <font color="blue">major customer</font>s and to the risk that the loss of a <font color="blue">major customer</font>     would <font color="blue">adversely affect</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">relationship with</font>     these customers is subject to change at any time</td>
    </tr>
    <tr>
      <td>We anticipate that a substantial portion of our <font color="blue">revenues <font color="blue">will continue</font></font> to     come from the Angio-Seal, which is <font color="blue">manufacture</font>d, marketed and <font color="blue">distributed by</font>     St</td>
    </tr>
    <tr>
      <td>Under  our <font color="blue">license <font color="blue">agreements</font> with</font> St</td>
    </tr>
    <tr>
      <td>Jude Medical, the Angio-Seal is     <font color="blue">manufacture</font>d, marketed and sold on a <font color="blue">worldwide basis by</font> St</td>
    </tr>
    <tr>
      <td>Two of our <font color="blue">significant</font> sources of revenue for the future are expected to be     sales of collagen to St</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font>for use in the Angio-Seal and royalty     <font color="blue">income from</font> the sale of the Angio-Seal <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success with</font> the     Angio-Seal depends in part on the time, effort and attention that St</td>
    </tr>
    <tr>
      <td>Jude     Medical devotes to the Angio-Seal <font color="blue">product line</font> and on their success in     <font color="blue">manufacturing</font>, marketing and selling the Angio-Seal <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>Under the     terms of our <font color="blue">agreements</font> with St</td>
    </tr>
    <tr>
      <td>Jude Medical, we have <font color="blue">no control over</font> the     pricing and <font color="blue">marketing strategy</font> for the Angio-Seal <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>Jude  Medical  to  <font color="blue">successfully</font> maintain levels of     <font color="blue">manufacturing</font> sufficient to meet anticipated demand, abide by applicable     <font color="blue">manufacturing</font> <font color="blue">regulations</font> and seek <font color="blue">reimbursement</font> approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font>    can terminate the <font color="blue">license agreement</font> for any reason upon 12 months notice</td>
    </tr>
    <tr>
      <td>At     such time, all sales and marketing, <font color="blue">manufacturing</font> and <font color="blue">distribution</font> rights to     the  Angio-Seal  would  be  returned  to  us</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font>may not     <font color="blue">successfully</font>  <font color="blue">pass future inspections</font> of its <font color="blue">manufacturing</font> <font color="blue">facility</font> or     <font color="blue">adequately</font> perform its <font color="blue">manufacturing</font>, marketing and <font color="blue">selling duties</font></td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">failure by</font> St</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font><font color="blue">may negatively impact</font> Angio-Seal unit sales and     <font color="blue">therefore reduce</font> our royalties</td>
    </tr>
    <tr>
      <td>If our <font color="blue">biomaterials</font> products are not successful, our operating results and     business may be <font color="blue">substantially impaired</font></td>
    </tr>
    <tr>
      <td>The success of our existing <font color="blue">biomaterials</font> products, as well as any we develop     in the future, depends on a variety of factors, including our ability to     continue to <font color="blue">manufacture</font>, sell and <font color="blue"><font color="blue">competitive</font>ly price</font> these products and the     <font color="blue">acceptance</font> of these <font color="blue">products by</font> the <font color="blue">medical profession</font></td>
    </tr>
    <tr>
      <td>In addition, we may     be  required to obtain <font color="blue">regulatory</font> approval for any future <font color="blue">biomaterials</font>     products</td>
    </tr>
    <tr>
      <td>We will require substantial <font color="blue"><font color="blue">additional</font> funds</font> to develop and market     our <font color="blue">biomaterials</font> products</td>
    </tr>
    <tr>
      <td>We expect to fund the growth of our <font color="blue">biomaterials</font>     business out of our operating income, but this operating <font color="blue">income may</font> not be     sufficient to develop new <font color="blue">biomaterials</font> products</td>
    </tr>
    <tr>
      <td>To date, we have relied on     strategic  partners  or  customers to market and sell our <font color="blue">biomaterials</font>     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we <font color="blue">will <font color="blue">commercialize</font></font> our products     <font color="blue">successfully</font> through our existing and developing <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our customers to market and obtain <font color="blue">regulatory</font> approvals for     their <font color="blue">biomaterials</font> products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> the efforts of our <font color="blue">biomaterials</font> customers in marketing their     products that include our <font color="blue">biomaterials</font> <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>There can be no assurance     that  our  customers’  end-use  products that include our <font color="blue">biomaterials</font>     <font color="blue"><font color="blue">components</font> will</font> be <font color="blue">commercialize</font>d <font color="blue">successfully</font> by our customers or that our     <font color="blue">customers will otherwise</font> be able to <font color="blue">compete <font color="blue">effectively</font></font> in their markets</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [23]Table of <font color="blue">Contents       </font>The markets for our products are <font color="blue">highly <font color="blue">competitive</font></font> and are likely to become     more <font color="blue">competitive</font>, and our <font color="blue"><font color="blue">competitors</font> may</font> be able to respond more quickly to     new or <font color="blue">emerging <font color="blue">technologies</font></font> and changes in <font color="blue">customer <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>The markets for our current and <font color="blue">proposed products</font> are fragmented, intensely     <font color="blue">competitive</font>,  subject  to  rapid  change  and sensitive to new product     <font color="blue">introduction</font>s and <font color="blue">enhancements</font></td>
    </tr>
    <tr>
      <td>We expect that the <font color="blue">competitive</font> environment     for our <font color="blue">products will become</font> more <font color="blue">intense as <font color="blue">additional</font> companies enter</font> our     markets and <font color="blue">as new techniques</font> and <font color="blue">technologies</font> are adopted</td>
    </tr>
    <tr>
      <td>Our <font color="blue">biomaterials</font>     and <font color="blue">medical devices compete directly</font> and <font color="blue">indirectly</font> for <font color="blue">customers with</font> a     range of products and <font color="blue">technologies</font> produced by a wide variety of companies,     as well as other processes and <font color="blue">procedures which</font> do not require the use of     our products or those of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Many of our existing <font color="blue">competitors</font>,     as well as a number of potential new <font color="blue">competitors</font>, have longer operating     histories in these markets, greater name <font color="blue">recognition</font>, larger customer bases     and greater financial, technical and marketing resources</td>
    </tr>
    <tr>
      <td>Our <font color="blue">biomaterials</font> products compete with the products of many of the larger     companies  in the industry</td>
    </tr>
    <tr>
      <td>(a subsidiary of Abbott Laboratories) and Vascular Solutions, Inc, amongst     other smaller <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The majority of <font color="blue">vascular sealing</font> is performed     through manual compression, which represents our <font color="blue">primary competition</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">TriActiv System</font> is <font color="blue">currently commercially available</font> in the <font color="blue">United Sates </font>and     Europe where our <font color="blue">competitors</font> include Boston Scientific Corporation, Johnson     and Johnson, Inc, Medtronic, Inc</td>
    </tr>
    <tr>
      <td>) and Abbott     Laboratories, <font color="blue">among others</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">competitors</font>  may  have broader <font color="blue">product line</font>s, which allow them to     negotiate exclusive, long-term supply contracts and <font color="blue">offer comprehensive</font>     pricing for their products</td>
    </tr>
    <tr>
      <td>Broader <font color="blue">product line</font>s may also provide our     <font color="blue">competitors</font> with a <font color="blue">significant</font> advantage in <font color="blue">marketing competing products</font> to     group <font color="blue">purchasing organizations</font> and other <font color="blue">managed care organizations</font> that are     <font color="blue">increasingly seeking</font> to <font color="blue">reduce costs through centralized purchasing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Greater     </font><font color="blue">financial resources</font> and <font color="blue">product <font color="blue">development</font> cap<font color="blue">abilities</font> may allow</font> our     <font color="blue">competitors</font> to respond more quickly to new or <font color="blue">emerging <font color="blue">technologies</font></font> and     changes in <font color="blue">customer <font color="blue">requirements</font></font> that may render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>Because a <font color="blue">significant</font> portion of our revenue depends on sales of medical     devices by our customers to the end-user market, we are <font color="blue">also affected by</font>     <font color="blue">competition within</font> the markets for these devices</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>within the     medical device <font color="blue">market could also</font> have an adverse effect on our business for     a variety of reasons, including that our <font color="blue">customers may compete directly with</font>     larger, dominant <font color="blue">manufacture</font>rs with extensive <font color="blue">product line</font>s and greater     sales,  marketing and <font color="blue">distribution</font> cap<font color="blue">abilities</font></td>
    </tr>
    <tr>
      <td>We are also unable to     control  other  factors  that  may impact the <font color="blue">commercialization</font> of our     <font color="blue">components</font> for end use products, such as marketing and <font color="blue">sales efforts</font> and     <font color="blue">competitive</font> pricing pressures within particular markets</td>
    </tr>
    <tr>
      <td>If our products are not <font color="blue">accepted by</font> the <font color="blue">medical community</font> or if our products     are replaced by new <font color="blue">technologies</font>, our business may suffer</td>
    </tr>
    <tr>
      <td>The success of our existing products depends on continued <font color="blue">acceptance</font> of     these <font color="blue">products by</font> the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict whether</font> or not     our <font color="blue">products <font color="blue">will continue</font></font> to be accepted and if that <font color="blue">acceptance</font> will be     sustained to over the long term</td>
    </tr>
    <tr>
      <td>The success of any products we develop in     the future will <font color="blue">depend on</font> the adoption of these <font color="blue">products by</font> our targeted     markets</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict how quickly</font>, if at all, the <font color="blue">medical community</font>     will accept our <font color="blue">future products</font> or the extent to which our <font color="blue">future products</font>     will be used</td>
    </tr>
    <tr>
      <td>If we encounter <font color="blue">difficult</font>ies introducing <font color="blue">future products</font> into     our  targeted  markets,  our  operating  results  and  business may be     <font color="blue">substantially impaired</font></td>
    </tr>
    <tr>
      <td>In addition, new <font color="blue">technologies</font> and <font color="blue">techniques may</font> be     developed which may render our current products, along with those under     <font color="blue">development</font>, obsolete</td>
    </tr>
    <tr>
      <td>The loss of, or <font color="blue">interruption</font> of supply from, key vendors could limit our     ability to <font color="blue">manufacture</font> our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">purchase certain materials</font> and <font color="blue">components</font> for our <font color="blue">products from various</font>     suppliers</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">components</font> are custom made for us, including many     of our absorbable polymer and suture raw <font color="blue">materials which</font> are used in our     custom polymer products across all markets</td>
    </tr>
    <tr>
      <td>Any loss of, or <font color="blue">interruption</font> of     supply  from, key vendors may require us to <font color="blue">find new vendors</font></td>
    </tr>
    <tr>
      <td>We could     experience production or <font color="blue"><font color="blue">development</font> delays while</font> we <font color="blue">seek new vendors</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [24]Table of <font color="blue">Contents       </font>We may have problems <font color="blue">manufacturing</font> and delivering our <font color="blue">biomaterials</font> products     in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">biomaterials</font> industry is an emerging area, using many <font color="blue">materials which</font>     are untested or <font color="blue">whose properties</font> are still not known</td>
    </tr>
    <tr>
      <td>Consequently, from     time to time we may experience <font color="blue">unanticipated <font color="blue">difficult</font>ies</font> in <font color="blue">manufacturing</font>     and  delivering  our  <font color="blue">biomaterials</font>  products  to  our customers</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">difficult</font>ies may</font> include an <font color="blue">inability</font> to meet customer demand, delays in     delivering products or quality control problems with certain <font color="blue">biomaterials</font>     products</td>
    </tr>
    <tr>
      <td>Our  use  of  <font color="blue">hazardous</font>  materials  <font color="blue">exposes us</font> to the risk of material     <font color="blue"><font color="blue">environmental</font> <font color="blue">li<font color="blue">abilities</font></font></font></td>
    </tr>
    <tr>
      <td>Because we use <font color="blue">hazardous</font> substances in our research and <font color="blue">development</font> and     <font color="blue">manufacturing</font> <font color="blue">operations</font>, we are <font color="blue">potentially</font> subject to material <font color="blue">li<font color="blue">abilities</font></font>     related to <font color="blue">personal injuries</font> or <font color="blue">property damages</font> that may be caused by     <font color="blue">hazardous</font>  substance  releases  or  <font color="blue">exposures at</font> or from our <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">Decontamination  </font>costs,  other  clean-up  costs and related damages or     <font color="blue">li<font color="blue">abilities</font></font> could substantially impair our business and operating results</td>
    </tr>
    <tr>
      <td>We are required to <font color="blue"><font color="blue">comply with</font> increasingly stringent laws</font> and <font color="blue">regulations</font>     governing  <font color="blue">environmental</font>  protection  and  <font color="blue">workplace safety</font>, including     <font color="blue"><font color="blue">requirements</font> governing</font> the handling, storage and disposal of <font color="blue">hazardous</font>     substances</td>
    </tr>
    <tr>
      <td>Jude Medical’s and our     <font color="blue">international</font> sales are subject to a number of risks that <font color="blue">could harm future</font>     <font color="blue">international</font>  sales  of  Angio-Seal  and  our ability to <font color="blue">successfully</font>     <font color="blue">commercialize</font> new products in <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>Many of our customers sell products <font color="blue">international</font>ly, <font color="blue"><font color="blue">additional</font>ly</font> St</td>
    </tr>
    <tr>
      <td>Jude     Medical sells the Angio-Seal <font color="blue">product line</font> <font color="blue">international</font>ly and pays us a     <font color="blue">royalty on each</font> unit sold</td>
    </tr>
    <tr>
      <td>We also sell the TriActiv device, as well as some     of our other products, in the <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>Our sales and royalties     from <font color="blue">international</font> sales of the Angio-Seal <font color="blue">product line</font> by St</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font>    and our revenues from our other <font color="blue">international</font> sales are subject to several     risks, including:           •   the impact of <font color="blue">recessions</font> in economies both within and outside the     <font color="blue">United States</font>;           •   unexpected changes in <font color="blue">regulatory</font> <font color="blue">requirements</font>, tariffs or other trade     barriers;           •   <font color="blue">weaker <font color="blue">intellectual</font> property rights protection</font> in some countries;           •   <font color="blue">fluctuations</font> in <font color="blue">exchange rates</font>;           •   <font color="blue">potentially</font> adverse tax consequences; and           •   political and <font color="blue">economic instability</font></td>
    </tr>
    <tr>
      <td>The  occurrence  of  any of these <font color="blue">events could seriously harm</font> St</td>
    </tr>
    <tr>
      <td>Jude     Medical’s or our future <font color="blue">international</font> sales</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">success depends</font> on key personnel</font>, the loss of <font color="blue">whom could impair</font> our     operating results and business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, to a <font color="blue">significant</font> extent, upon the efforts and <font color="blue">abilities</font>     of Joseph W Kaufmann, Douglas G Evans, Wendy F DiCicco and other members     of <font color="blue">senior management</font></td>
    </tr>
    <tr>
      <td>The loss of the services of one or more of these key     <font color="blue">employees could harm</font> our operating results and business</td>
    </tr>
    <tr>
      <td>In addition, we     will not be <font color="blue">successful unless</font> we can attract and retain <font color="blue">skilled personnel</font>,     <font color="blue">particularly</font> in the areas of research and product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our  failure  to expand our <font color="blue">management systems</font> and controls to support     anticipated growth or <font color="blue">integrate future <font color="blue">acquisition</font>s could seriously harm</font> our     operating results and business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> continue to grow and we expect this expansion to <font color="blue">continue as</font>     we  execute  our  business  strategy</td>
    </tr>
    <tr>
      <td><font color="blue">Sustaining </font>our growth has placed     <font color="blue">significant</font> demands on management and our administrative, operational,     information technology, <font color="blue">manufacturing</font>, financial and <font color="blue">personnel resources</font></td>
    </tr>
    <tr>
      <td>Accordingly, our future operating results will <font color="blue">depend on</font> the ability of our     officers and other <font color="blue">key employees</font> to continue to implement and improve our     operational, client support and <font color="blue">financial control systems</font>, and <font color="blue">effectively</font>     expand, train and manage our <font color="blue">employee base</font></td>
    </tr>
    <tr>
      <td>We may not be able to manage our     growth <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [25]Table of <font color="blue">Contents       </font>Any <font color="blue">acquisition</font>s, including our <font color="blue">acquisition</font> of <font color="blue">IntraLuminal Therapeutics </font>in     May 2006, that we undertake could be <font color="blue">difficult</font> to integrate, disrupt our     business, <font color="blue">dilute stockholder value</font> and harm our operating results</td>
    </tr>
    <tr>
      <td>We  may  acquire  or  make  <font color="blue">investment</font>s  in  <font color="blue">complementary businesses</font>,     <font color="blue">technologies</font>, services or products if <font color="blue">appropriate opportunities</font> arise</td>
    </tr>
    <tr>
      <td>The     process of integrating any acquired business, technology, service or product     into  our  business  and <font color="blue">operations</font> may result in unforeseen operating     <font color="blue">difficult</font>ies and <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td><font color="blue">Integration </font>of any acquired <font color="blue">company also may</font>     consume much of our management’s time and attention that <font color="blue">could otherwise</font> be     available for ongoing <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>Moreover, the anticipated     benefits of any <font color="blue">acquisition</font> may not be realized</td>
    </tr>
    <tr>
      <td>Furthermore, we may be     unable to identify, negotiate or finance future <font color="blue">acquisition</font>s <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">acquisition</font>s could result in <font color="blue">potentially</font> dilutive issuances of equity     securities or the incurrence of debt, contingent <font color="blue">li<font color="blue">abilities</font></font> or <font color="blue">amortization</font>     expenses related to goodwill and other <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>Our  future  operating  results  are <font color="blue">difficult</font> to predict and may vary     <font color="blue">significant</font>ly from quarter to quarter</td>
    </tr>
    <tr>
      <td>Our operating results have varied <font color="blue">significant</font>ly from quarter to quarter in     the past and are likely to <font color="blue">vary substantially</font> in the future as a result of a     number of factors, some of which are not in our control, including:           •   <font color="blue">market <font color="blue">perception</font></font> and customer <font color="blue">acceptance</font> of our products;           •   <font color="blue">market <font color="blue">perception</font></font> and <font color="blue">acceptance</font> of our customer’s products;           •   our efforts to <font color="blue">increase sales</font> of our <font color="blue">biomaterials</font> products;           •   our efforts to <font color="blue">commercialize</font> our <font color="blue"><font color="blue">endovascular</font> products</font> through our     existing and developing <font color="blue">sales force</font>;           •   our efforts to gain <font color="blue">CE Mark and FDA </font>approval for <font color="blue">future generations</font> of     <font color="blue">endovascular</font> devices;           •   the loss of <font color="blue">significant</font> orders;           •   changes in our <font color="blue">relationship with</font> St</td>
    </tr>
    <tr>
      <td>Jude Medical;           •   our <font color="blue">establishment</font> of <font color="blue">strategic alliances</font> or <font color="blue">acquisition</font>s;           •   <font color="blue">timely implementation</font> of new and <font color="blue">improved products</font>;           •   delays in obtaining <font color="blue">regulatory</font> approvals;           •   <font color="blue">reimbursement</font> for our products;           •   <font color="blue">increased competition</font>; and           •   <font color="blue">litigation</font> concerning <font color="blue">intellectual</font> property rights in the medical     device industry</td>
    </tr>
    <tr>
      <td>You  should not rely upon our results of <font color="blue">operations</font> for any particular     quarter  as  an <font color="blue">indication</font> of our results for a full year or any other     quarter</td>
    </tr>
    <tr>
      <td>Risks Related to Our Intellectual Property        If  we  are  unable to protect our patents and <font color="blue"><font color="blue">proprietary</font> rights</font>, our     reputation and <font color="blue">competitive</font>ness in the <font color="blue">marketplace may</font> be <font color="blue">materially damaged</font></td>
    </tr>
    <tr>
      <td>We regard our patents, <font color="blue">biomaterials</font> trade secrets and other <font color="blue">intellectual</font>     <font color="blue">property as important</font> to our success</td>
    </tr>
    <tr>
      <td>We rely upon patent law, trade secret     protection, confidentiality <font color="blue">agreements</font> and <font color="blue">license <font color="blue">agreements</font> with</font> St</td>
    </tr>
    <tr>
      <td>Jude     Medical to protect our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Although we have registered     certain  of  our  patents  with  applicable <font color="blue">international</font> <font color="blue">governmental</font>     authorities, effective patent protection may not be available in every     country in which our products are made available, and we have not sought     protection for our <font color="blue">intellectual</font> property in <font color="blue">every country</font> where our products     may be sold</td>
    </tr>
    <tr>
      <td>The steps we take to protect our <font color="blue"><font color="blue">proprietary</font> rights</font> may not be     adequate to ensure that <font color="blue"><font color="blue">third parties</font> will</font> not infringe or <font color="blue">otherwise violate</font>     our patents or similar <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________    [26]Table of <font color="blue">Contents       </font>We may be accused of <font color="blue">infringing upon</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others and     any related <font color="blue">litigation</font> <font color="blue">could materially</font> damage our operating results and     business</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that we have violated their <font color="blue">intellectual</font> property     rights</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse de<font color="blue">termination</font></font> in any <font color="blue">intellectual</font> property <font color="blue">litigation</font> or     interference proceedings brought against us could prohibit us from selling     our products, subject us to <font color="blue">significant</font> <font color="blue">li<font color="blue">abilities</font></font> to <font color="blue">third parties</font> or     require us to seek licenses from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>The costs <font color="blue">associated with</font>     these <font color="blue">license arrangements may</font> be substantial and could include ongoing     royalties</td>
    </tr>
    <tr>
      <td>Furthermore, the <font color="blue">necessary</font> licenses may not be available to us on     satisfactory terms, if at all</td>
    </tr>
    <tr>
      <td>Adverse <font color="blue">de<font color="blue">termination</font>s</font> in a judicial or     <font color="blue">administrative proceeding</font> or failure to obtain <font color="blue">necessary</font> licenses could     <font color="blue">prevent us</font> from <font color="blue">manufacturing</font> and selling our products</td>
    </tr>
    <tr>
      <td>Any of these claims,     with or without merit, could subject us to costly <font color="blue">litigation</font> and divert the     attention of key personnel</td>
    </tr>
    <tr>
      <td>We do not own or control the use of the Angio-Seal device trademark</td>
    </tr>
    <tr>
      <td>The  term  Angio-Seal is a trademark of St</td>
    </tr>
    <tr>
      <td>All goodwill     <font color="blue">generated by</font> the marketing and sales of <font color="blue">devices bearing</font> the Angio-Seal     <font color="blue">trademark belongs</font> to St</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font>and not to us</td>
    </tr>
    <tr>
      <td><font color="blue">Should the St</font></td>
    </tr>
    <tr>
      <td>Jude     Medical license <font color="blue">agreements</font> terminate, we would not have the right to call     any of our products “Angio-Seal” unless we purchase or license the trademark     from St</td>
    </tr>
    <tr>
      <td>Without rights to the Angio-Seal trademark, we would     have to market our <font color="blue">products under</font> a <font color="blue">different trademark</font></td>
    </tr>
    <tr>
      <td>Moreover, upon the     <font color="blue">termination</font> of the St</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font>license <font color="blue">agreements</font>, St</td>
    </tr>
    <tr>
      <td><font color="blue">Jude Medical </font>    would have the right to <font color="blue">compete against us by selling collagen</font> and puncture     <font color="blue">closure devices under</font> the Angio-Seal trademark</td>
    </tr>
    <tr>
      <td>Thus, purchasers of puncture     closure  <font color="blue">devices may</font> be more likely to recognize and <font color="blue">purchase products</font>     labeled Angio-Seal <font color="blue">regardless</font> of whether those <font color="blue">devices originate from us</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry        We <font color="blue">may face product <font color="blue">liability</font></font> claims that could result in costly <font color="blue">litigation</font>     and <font color="blue">significant</font> <font color="blue">li<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical testing</font>, <font color="blue">manufacture</font> and sale of <font color="blue">medical products involve</font> an     <font color="blue">inherent risk</font> that <font color="blue">human subjects</font> in <font color="blue">clinical testing</font> or consumers of the     <font color="blue">products may</font> suffer serious bodily injury or <font color="blue">death due</font> to side effects or     other  <font color="blue">unintended negative reactions</font> to our products</td>
    </tr>
    <tr>
      <td>Accordingly, the     <font color="blue">clinical testing</font>, <font color="blue">manufacture</font> and sale of our products entail <font color="blue">significant</font>     risk of product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>The medical device industry in general has     been  subject to <font color="blue">significant</font> product <font color="blue">liability</font> <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any product     <font color="blue">liability</font> claims, with or without merit, could result in costly <font color="blue">litigation</font>,     reduced sales, <font color="blue">significant</font> <font color="blue">li<font color="blue">abilities</font></font> and diversion of our management’s     time, attention and resources</td>
    </tr>
    <tr>
      <td>We cannot be sure that our product <font color="blue">liability</font>     <font color="blue">insurance coverage</font> is adequate or that it <font color="blue">will continue</font> to be available to     us on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We <font color="blue">face uncertainty</font> relating to <font color="blue">third party</font> <font color="blue">reimbursement</font> for our products</td>
    </tr>
    <tr>
      <td>We  could  be <font color="blue">seriously harmed by</font> changes in <font color="blue">reimbursement</font> policies of     <font color="blue">governmental</font> or private healthcare payers, <font color="blue">particularly</font> to the extent any     changes affect <font color="blue">reimbursement</font> for <font color="blue">catheterization procedures</font> in which our     Angio-Seal products are used</td>
    </tr>
    <tr>
      <td>Physicians, hospitals and other users of our     <font color="blue">products may</font> fail to obtain sufficient <font color="blue">reimbursement</font> from healthcare payers     for procedures in which our products are used or adverse changes may occur     in  <font color="blue">governmental</font>  and  private  third-party  payers’  policies  toward     <font color="blue">reimbursement</font> for these procedures</td>
    </tr>
    <tr>
      <td>Our  products  and  <font color="blue">manufacturing</font>  <font color="blue">activities</font> are subject to extensive     <font color="blue">governmental</font> regulation that could make it more expensive and time consuming     for us to <font color="blue">introduce new</font> and <font color="blue">improved products</font></td>
    </tr>
    <tr>
      <td>Our  products  and  <font color="blue">manufacturing</font>  <font color="blue">activities</font> are subject to extensive     <font color="blue">regulation by</font> a number of <font color="blue">governmental</font> agencies, including the FDA and     comparable <font color="blue">international</font> agencies</td>
    </tr>
    <tr>
      <td>We are required to:           •   obtain the approval of the FDA and <font color="blue">international</font> agencies before we     can market and sell new products;           •   satisfy these agencies’ <font color="blue">requirements</font> for all of our labeling, sales     and promotional materials in <font color="blue">connection</font> with our existing products;                                           25     ______________________________________________________________________    [27]Table of <font color="blue">Contents       </font>  •   <font color="blue">comply with</font> all applicable <font color="blue">manufacturing</font> <font color="blue">regulations</font>; and           •   <font color="blue">undergo rigorous inspections by</font> these agencies</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with the <font color="blue">regulations</font> of these <font color="blue">agencies may delay</font> or <font color="blue">prevent us</font>     <font color="blue">from introducing</font> any new or <font color="blue">improved products</font>, including <font color="blue">future generations</font>     of  the  <font color="blue">TriActiv System</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may be subject to sanctions,     including temporary or <font color="blue">permanent suspension</font> of <font color="blue">operations</font>, product recalls     and  marketing  <font color="blue">restrictions</font>  if  we  fail to <font color="blue">comply with</font> the laws and     <font color="blue">regulations</font> pertaining to our business</td>
    </tr>
    <tr>
      <td>We are also required to <font color="blue">demonstrate compliance with</font> the FDA’s Quality System     Regulations</td>
    </tr>
    <tr>
      <td>The  FDA enforces its <font color="blue">Quality System Regulations </font>through     pre-approval and periodic post-approval inspections</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font>     relate to product testing, vendor qualification, design control and quality     assurance, as well as the maintenance of records and <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>If we     are unable to conform to these <font color="blue">regulations</font>, we will be required to locate     <font color="blue">alternative</font>  <font color="blue">manufacture</font>rs that do conform</td>
    </tr>
    <tr>
      <td><font color="blue">Identifying </font>and qualifying     <font color="blue">alternative</font> <font color="blue">manufacture</font>rs may be a long, costly and <font color="blue">difficult</font> process and     could seriously harm our business</td>
    </tr>
    <tr>
      <td>The FDA and <font color="blue">international</font> <font color="blue">regulatory</font> agencies may also limit the <font color="blue">indication</font>s     for which our products are approved</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulatory</font> agencies may restrict     or <font color="blue">withdraw approvals</font> we have received if <font color="blue">additional</font> information becomes     available to support this action</td>
    </tr>
    <tr>
      <td>Risks Related To Our Securities        The <font color="blue">trading price</font> of our <font color="blue">common stock</font> is likely to <font color="blue">fluctuate substantially</font>     in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> may fluctuate widely as a result of a     number of factors, some of which are not in our control, including:           •   our ability to meet or exceed our own forecasts or <font color="blue">expectations</font> of     analysts or investors;           •   quarter to <font color="blue">quarter variations</font> in our operating results;           •   <font color="blue">announcements</font> regarding clinical <font color="blue">activities</font> or new <font color="blue">products by</font> us or     our <font color="blue">competitors</font>;           •   <font color="blue">general conditions</font> in the medical device industry;           •   changes in our own forecasts or earnings estimates <font color="blue">by analysts</font>;           •   our customers and licensees’ ability to meet or exceed the forecasts     or <font color="blue">expectations</font> of analysts or investors;           •   price and volume <font color="blue">fluctuations</font> in the overall stock market, which have     <font color="blue">particularly</font> affected the <font color="blue"><font color="blue">market price</font>s</font> of many medical device companies;     and           •   <font color="blue">general economic conditions</font></td>
    </tr>
    <tr>
      <td>In addition, the market for our stock has experienced, and <font color="blue">may continue</font> to     experience, price and volume <font color="blue">fluctuations</font> unrelated or <font color="blue">disproportionate</font> to     our operating performance</td>
    </tr>
    <tr>
      <td>In the     past, following periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a company’s     securities, securities class action <font color="blue">litigation</font> has <font color="blue">often been instituted</font>     against that company</td>
    </tr>
    <tr>
      <td>If any securities <font color="blue">litigation</font> is initiated against us,     with  or  without  merit,  we  could  incur substantial costs, and our     management’s attention and resources could be diverted from our business</td>
    </tr>
    <tr>
      <td>Future sales of our <font color="blue">common stock</font> in the <font color="blue">public <font color="blue">market by management</font></font> and     other <font color="blue">stockholders</font> with <font color="blue">significant</font> holdings could cause our stock price to     fall</td>
    </tr>
    <tr>
      <td>Sales of a substantial number of shares of our <font color="blue">common stock</font> in the public     <font color="blue">market by management</font> or other <font color="blue">significant</font> <font color="blue">stockholders</font> or the <font color="blue">perception</font>     that <font color="blue">such sales could</font> occur, could cause the <font color="blue">market price</font> of our common     stock to decline or <font color="blue">adversely affect</font> our <font color="blue">future ability</font> to <font color="blue">raise capital</font>     through an offering of <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________    [28]Table of <font color="blue">Contents       </font>Our <font color="blue">second amended</font> and <font color="blue">restated <font color="blue">certificate</font></font> of <font color="blue">incorporation</font> and <font color="blue">Delaware     </font><font color="blue">law may discourage</font> an <font color="blue">acquisition</font> of our company</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">second amended</font> and <font color="blue">restated <font color="blue">certificate</font></font> of <font color="blue">incorporation</font>     <font color="blue">and Delaware </font>law could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire     us, even if doing so would be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
  </tbody>
</table>